{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T13:13:41Z","timestamp":1791810821891,"version":"4.3.4"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.cct.2023.107176","type":"journal-article","created":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T18:45:19Z","timestamp":1680720319000},"page":"107176","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"special_numbering":"C","title":["A phase 2, adaptive randomized, double-blind, placebo-controlled, multicenter, 52-week study of HM15211 in patients with biopsy-confirmed non-alcoholic steatohepatitis \u2013 Study design and rationale of HM-TRIA-201 study"],"prefix":"10.1016","volume":"130","author":[{"given":"Manal F.","family":"Abdelmalek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willian","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Lawitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Filozof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyungjin","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunhye","family":"Baek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JaeDuk","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seungjae","family":"Baek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cct.2023.107176_bb0005","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology."},{"key":"10.1016\/j.cct.2023.107176_bb0010","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/TP.0b013e31827afb3a","article-title":"Evolving frequency and outcomes of liver transplantation based on etiology of liver disease","volume":"95","author":"Singal","year":"2013","journal-title":"Transplantation."},{"key":"10.1016\/j.cct.2023.107176_bb0015","doi-asserted-by":"crossref","first-page":"5250","DOI":"10.2174\/13816128113199990344","article-title":"Pathophysiology of NASH: perspectives for a targeted treatment","volume":"19","author":"Marra","year":"2013","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.cct.2023.107176_bb0020","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1007\/s11901-018-0425-7","article-title":"Pathogenesis of NASH: the impact of multiple pathways","volume":"17","author":"Noureddin","year":"2018","journal-title":"Curr. Hepatol. Rep."},{"key":"10.1016\/j.cct.2023.107176_bb0025","doi-asserted-by":"crossref","first-page":"R240","DOI":"10.1530\/EC-21-0048","article-title":"Nonalcoholic steatohepatitis: global impact and clinical consequences","volume":"10","author":"Kabarra","year":"2021","journal-title":"Endocr. Conn."},{"key":"10.1016\/j.cct.2023.107176_bb0030","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"REGENERATE study investigators, Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet."},{"key":"10.1016\/j.cct.2023.107176_bb0035","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jhep.2021.10.029","article-title":"Non-invasive evaluation of response to obeticholic acid in patients with NASH: results from the REGENERATE study","volume":"76","author":"Rinella","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cct.2023.107176_bb0040","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S0140-6736(18)30474-4","article-title":"NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"391","author":"Harrison","year":"2018","journal-title":"Lancet."},{"key":"10.1016\/j.cct.2023.107176_bb0045","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/s41591-021-01425-3","article-title":"Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial","volume":"27","author":"Harrison","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.cct.2023.107176_bb0050","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"Harrison","year":"2019","journal-title":"Lancet."},{"key":"10.1016\/j.cct.2023.107176_bb0055","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1053\/j.gastro.2018.07.027","article-title":"GS-0976 reduces hepatic steatosis and Fibrosis markers in patients with nonalcoholic fatty liver disease","volume":"155","author":"Loomba","year":"2018","journal-title":"Gastroenterology."},{"key":"10.1016\/j.cct.2023.107176_bb0060","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1016\/j.cgh.2018.04.042","article-title":"Acetyl-CoA carboxylase inhibitor GS-0976 for 12 weeks reduces hepatic De novo lipogenesis and steatosis in patients with nonalcoholic steatohepatitis","volume":"16","author":"Lawitz","year":"2018","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.cct.2023.107176_bb0065","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"NATIVE study group, A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cct.2023.107176_bb0070","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of incretins: GLP-1 and GIP","volume":"132","author":"Baggio","year":"2007","journal-title":"Gastroenterology."},{"key":"10.1016\/j.cct.2023.107176_bb0075","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous Semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cct.2023.107176_bb0080","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-003995","article-title":"Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial","volume":"3","author":"Armstrong","year":"2013","journal-title":"BMJ Open"},{"key":"10.1016\/j.cct.2023.107176_bb0085","doi-asserted-by":"crossref","DOI":"10.2337\/db20-1830-P","article-title":"1830-P: therapeutic effect of a novel long-acting GLP-1\/GIP\/glucagon triple agonist (HM15211) in CDHFD-induced NASH and Fibrosis mice","volume":"69","author":"Choi","year":"2020","journal-title":"Diabetes."},{"key":"10.1016\/j.cct.2023.107176_bb0090","author":"Choi"},{"key":"10.1016\/j.cct.2023.107176_bb0095","doi-asserted-by":"crossref","first-page":"S124","DOI":"10.1016\/S0168-8278(20)30765-0","article-title":"HM15211, a novel GLP-1\/GIP\/glucagon triple-receptor co-agonist significantly reduces liver fat and body weight in obese subjects with non-alcoholic fatty liver disease: a phase 1b\/2a, multi-center, randomized, placebo-controlled trial","volume":"73","author":"Abdelmalek","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cct.2023.107176_bb0100","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Nonalcoholic steatohepatitis clinical research network, design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology."},{"key":"10.1016\/j.cct.2023.107176_bb0105","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/hep4.1079","article-title":"Clinical endpoints and adaptive clinical trials in precirrhotic nonalcoholic steatohepatitis: facilitating development approaches for an emerging epidemic","volume":"1","author":"Filozof","year":"2017","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.cct.2023.107176_bb0110","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/phar.2489","article-title":"Emerging therapies for the treatment of nonalcoholic steatohepatitis: a systematic review","volume":"41","author":"Guirguis","year":"2021","journal-title":"Pharmacotherapy."},{"key":"10.1016\/j.cct.2023.107176_bb0115","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1136\/gutjnl-2019-319104","article-title":"Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges","volume":"69","author":"Dufour","year":"2020","journal-title":"Gut."},{"key":"10.1016\/j.cct.2023.107176_bb0120","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.2337\/dc19-1892","article-title":"Effects of novel dual GIP and GLP-1 receptor agonist Tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes","volume":"43","author":"Hartman","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cct.2023.107176_bb0125","author":"Eli Lilly and Company"},{"key":"10.1016\/j.cct.2023.107176_bb0130","series-title":"Anti-Fibrotic Effect of a Novel Long-Acting GLP-1\/GIP\/Glucagon Triple Agonist (HM15211) in BDL-Induced Liver Fibrosis Mice - Media Centre | EASD","author":"Kim","year":"2020"},{"key":"10.1016\/j.cct.2023.107176_bb0135","doi-asserted-by":"crossref","first-page":"656","DOI":"10.2337\/db21-656-P","article-title":"656-P: Antifibrotic potential of a novel long-acting glucagon\/GIP\/GLP-1 triple agonist (HM15211) in preclinical models of Fibrosis","volume":"70","author":"Kim","year":"2021","journal-title":"Diabetes."},{"key":"10.1016\/j.cct.2023.107176_bb0140","series-title":"Draft Reflection Paper on Regulatory Requirements for the Development of Medicinal Products Chronic Non-Infectious Liver Diseases (PBC, PSC, NASH)","author":"EMA","year":"2018"},{"key":"10.1016\/j.cct.2023.107176_bb0145","author":"Noncirrhotic Nonalcoholic Steatohepatitis With Liver Fibrosis"},{"key":"10.1016\/j.cct.2023.107176_bb0150","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/hep.24376","article-title":"Endpoints and clinical trial design for nonalcoholic steatohepatitis","volume":"54","author":"Sanyal","year":"2011","journal-title":"Hepatology."},{"key":"10.1016\/j.cct.2023.107176_bb0155","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.cct.2016.02.012","article-title":"Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR phase 2b study design","volume":"47","author":"Friedman","year":"2016","journal-title":"Contemp. Clin. Trial."},{"key":"10.1016\/j.cct.2023.107176_bb0160","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1002\/hep.29477","article-title":"A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis","volume":"67","author":"Friedman","year":"2018","journal-title":"Hepatology."},{"key":"10.1016\/j.cct.2023.107176_bb0165","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.cct.2023.107176_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2019.105889","article-title":"A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: study design of the TANDEM trial","volume":"88","author":"Pedrosa","year":"2020","journal-title":"Contemp. Clin. Trial."}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155171442300099X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155171442300099X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T08:59:14Z","timestamp":1761555554000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S155171442300099X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":34,"alternative-id":["S155171442300099X"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2023.107176","relation":{},"ISSN":["1551-7144"],"issn-type":[{"value":"1551-7144","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase 2, adaptive randomized, double-blind, placebo-controlled, multicenter, 52-week study of HM15211 in patients with biopsy-confirmed non-alcoholic steatohepatitis \u2013 Study design and rationale of HM-TRIA-201 study","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cct.2023.107176","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107176"}}